Spots Global Cancer Trial Database for acute myeloid leukemia post cytotoxic therapy
Every month we try and update this database with for acute myeloid leukemia post cytotoxic therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia | NCT04284787 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute... | Azacitidine Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Pembrolizumab Venetoclax | 60 Years - | National Cancer Institute (NCI) | |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | NCT04214249 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cytarabine Daunorubicin Hy... Echocardiograph... Hematopoietic C... Idarubicin Hydr... Multigated Acqu... Pembrolizumab Punch Biopsy | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02642965 | Acute Myeloid L... Recurrent Child... Secondary Acute... | Cytarabine Filgrastim Fludarabine Pho... Laboratory Biom... Liposome-encaps... Pharmacological... | 1 Year - 21 Years | Children's Oncology Group | |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | NCT03953898 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Biospecimen Col... Bone Marrow Asp... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | NCT04802161 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myeloproliferat... | Biospecimen Col... Bone Marrow Asp... Liposome-encaps... Pomalidomide | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | NCT04726241 | Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Juvenile Myelom... Mixed Phenotype... Myelodysplastic... Myelodysplastic... Myeloid Leukemi... | Biospecimen Col... | - 22 Years | LLS PedAL Initiative, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
